LenioBio Secures €3.7 Million in Funding from EU4Health to Advance ALiCE® for Rapid and Cost-Effective Protein-Based Drug Manufacturing
[City, State] – July 23, 2025 – LenioBio, a pioneering biotechnology company, is pleased to announce it has secured a significant funding round of €3.7 million from EU4Health. This crucial investment will be dedicated to the further development and commercialization of LenioBio’s innovative ALiCE® (Antibody Lytic Cell Expansion) platform, aiming to revolutionize the production of protein-based therapeutics.
The EU4Health funding underscores the immense potential of LenioBio’s technology to address a critical need within the pharmaceutical industry: the efficient and cost-effective manufacturing of complex protein-based medicines. These advanced therapies, which include biologics like antibodies, enzymes, and vaccines, are vital for treating a wide range of diseases, from cancer and autoimmune disorders to rare genetic conditions. However, their production often involves lengthy development cycles and substantial costs, limiting accessibility and broader patient benefit.
LenioBio’s ALiCE® platform offers a groundbreaking solution to these challenges. By leveraging proprietary cell expansion technology, ALiCE® enables the rapid and scalable production of therapeutic proteins. This innovative approach promises to significantly reduce manufacturing timelines and expenses compared to traditional methods, paving the way for faster development and broader patient access to life-saving treatments.
The €3.7 million investment will empower LenioBio to accelerate key aspects of its ALiCE® development program. This includes further optimizing the ALiCE® platform for enhanced protein yields and quality, expanding its capabilities for producing a diverse range of protein therapeutics, and strengthening its manufacturing infrastructure to meet future market demands. The funding will also support the company’s efforts to forge strategic partnerships within the pharmaceutical ecosystem, accelerating the translation of ALiCE®-produced therapeutics into clinical use.
“We are incredibly honored and excited to receive this substantial funding from EU4Health,” said [Name and Title of LenioBio Spokesperson]. “This investment is a testament to the transformative potential of our ALiCE® platform and its ability to address the pressing need for more accessible and affordable protein-based medicines. This support will be instrumental in our mission to democratize the production of these vital therapies, ultimately benefiting patients worldwide.”
LenioBio’s vision is to establish ALiCE® as the go-to manufacturing solution for next-generation protein therapeutics. With this significant funding from EU4Health, the company is well-positioned to achieve this goal, making a tangible impact on global health by accelerating the development and availability of innovative treatments.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘LenioBio obtient un financement de 3,7 millions d’euros de l’UE4Health pour développer ALiCE® en vue d’une production rapide et rentable de médicaments à base de protéines’ at 2025-07-23 07:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.